SAN FRANCISCO — Among patients with symptomatic, severe native aortic regurgitation at high surgical risk, the JenaValve Trilogy transcatheter heart valve system (JenaValve Technology) met its primary ...
Philips Respironics initiated a voluntary recall to address a potentially defective component on the Trilogy Ventilator power management board, which could affect the function of the device. If this ...
WASHINGTON, DC—Further follow-up from the ALIGN-AR trial confirm the safety and continued efficacy of the Trilogy heart valve system (JenaValve) for the treatment of patients with severe, symptomatic ...
IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced results from an ...
Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...
MURRYSVILLE, Pa., Feb. 19, 2014 /PRNewswire/ -- Respironics, Inc., a Philips Healthcare business, today announced a worldwide recall of approximately 600 Philips Respironics Trilogy Ventilators, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback